QCM Cayman’s BioCryst Pharmaceuticals BCRX Stock Holding History

QCM Cayman’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-11,719	Closed	-$40K	–	276
2020 Q3	$40K	Buy	+11,719	New	+$50.2K	0.07%	178

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

QCM Cayman's BCRX Position: Q4 2020 in Review

QCM Cayman sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2020, closing a stake of 11,719 shares — an estimated $40K sold.

QCM Cayman first reported a position in BCRX in Q3 2020 and held it in 1 quarter. The position peaked at $40K in Q3 2020. 177 funds tracked by Wall St. Rank hold BCRX as of Q4 2020.

QCM Cayman reported no remaining BioCryst Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
QCM Cayman sold 11,719 BioCryst Pharmaceuticals shares in Q4 2020, an estimated $40K.
QCM Cayman first reported a position in BioCryst Pharmaceuticals in Q3 2020 and held it in 1 quarter.
QCM Cayman's BioCryst Pharmaceuticals position peaked at $40K in Q3 2020.
177 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2020.

Based on QCM Cayman's 13F filing for Q4 2020, filed 12 Feb 2021.